TY - JOUR
T1 - Lipid biomarkers for the peroxisomal and lysosomal disorders
T2 - Their formation, metabolism and measurement
AU - Mashima, Ryuichi
AU - Maekawa, Masamitsu
N1 - Funding Information:
This work was supported by grants-in-aid for scientific research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (16K08958) to R Mashima. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2018 Future Medicine Ltd.
PY - 2018/1
Y1 - 2018/1
N2 - Lipid biomarkers play important roles in the diagnosis of and monitoring of treatment in peroxisomal disorders and lysosomal storage disorders. Today, a variety of lipids, including very long chain fatty acids, glycolipids, bile acids and the oxidation products of cholesterol, have been considered as biomarkers for these disorders. In this brief review, the authors summarized the recent advances regarding these lipid biomarkers in terms of their formation, metabolism and measurement in these disorders. An understanding of these biomarkers will offer a key to the development of novel diagnoses and help create more effective therapies in the future.
AB - Lipid biomarkers play important roles in the diagnosis of and monitoring of treatment in peroxisomal disorders and lysosomal storage disorders. Today, a variety of lipids, including very long chain fatty acids, glycolipids, bile acids and the oxidation products of cholesterol, have been considered as biomarkers for these disorders. In this brief review, the authors summarized the recent advances regarding these lipid biomarkers in terms of their formation, metabolism and measurement in these disorders. An understanding of these biomarkers will offer a key to the development of novel diagnoses and help create more effective therapies in the future.
KW - 1-hexacosanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC26:0)
KW - bile acids
KW - cholesterol oxidation products
KW - globotriaosylceramide
KW - liquid chromatography-tandem mass spectrometry
KW - lysosomal storage disorders
KW - peroxisomal disorders
UR - http://www.scopus.com/inward/record.url?scp=85038915373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038915373&partnerID=8YFLogxK
U2 - 10.2217/bmm-2017-0225
DO - 10.2217/bmm-2017-0225
M3 - Review article
C2 - 29235891
AN - SCOPUS:85038915373
VL - 12
SP - 83
EP - 95
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
SN - 1752-0363
IS - 1
ER -